Immunome, Inc. Email Format
Biotechnology ResearchWashington, United States201-500 Employees
Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. Based in Bothell, Washington, the company aims to deliver first-in-class and best-in-class treatments that improve outcomes for patients with solid tumors and desmoid tumors. Leadership includes veterans who helped design, develop, and commercialize targeted cancer therapies, including antibody-drug conjugates. Its pipeline features varegacestat (AL102), a gamma secretase inhibitor in Phase 3 for desmoid tumors, for which an NDA was submitted to the FDA in 2026; IM-1021, a ROR1-targeted ADC in Phase 1; and IM-3050, a FAP-targeted radioligand that has recently received IND clearance. The company is advancing additional preclinical ADCs—IM-1617, IM-1335, and IM-1340—for undisclosed targets expressed in multiple solid tumors.